Creating impactful solutions for other infectious diseases
We are looking to initiate strategic partnerships with other biotechnology and pharmaceutical companies for the co-development of novel antibody therapies. Our VHH platform has the potential to generate impactful solutions for the prevention and treatment of a broad range of diseases where multi-specific antibodies can make a difference. By joining forces, we can provide relief to patients beyond ExeVir’s initial targets COVID-19, dengue, and pandemic preparedness.
Leveraging the unique expertise present in ExeVir and our research partner VIB, we can develop new VHH antibodies up to IND-ready. We are looking for partners to provide the capacity and expertise to develop these therapeutics further into market-ready products.
Do you want to learn more or discuss an opportunity to collaborate?
Are you interested in learning more about the opportunity to participate in future funding rounds?
Maturing our product portfolio
ExeVir is backed by a strong international investor syndicate, raising €42 million in a Series A and a further €16.5 million in non-dilutive funding. Additional funding rounds will be needed for the clinical development of our first compounds and to expand our current portfolio.